Legal status in Thailand

Per-substance legal status for Thailand, from sourced statutes where available. Legal information, not legal advice; drug laws change, so confirm with the destination’s embassy or drug authority before you travel.

74 confirmed substances14 not individually verifiedLast updated September 21, 2026

Confirmed legal status

25I-NBOMe

Legal status: 25I-NBOMe is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries 25I-NBOMe as an entry beneath it. This table's 2C-I row records 25I-NBOMe as the near entry it rejected, so the N-benzyl compound is placed and the phenethylamine it derives from is not. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of 25I-NBOMe triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. The 2C-I row in this table rejected 25I-NBOMe as a near entry, so the section 145 exposure stated here belongs to the N-benzyl compound and does not travel back to the phenethylamine it derives from.
If prescribed / medical: 25I-NBOMe sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for 25I-NBOMe. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. A blotter sold as a 2C compound is not this entry unless it analyses as 25I-NBOMe, and the two rows carry different findings, one placed under section 145 and one left open.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: 25I-NBOMe was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check which compound an analysis actually names, because this table places 25I-NBOMe and leaves 2C-I unresolved. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for 25I-NBOMe is printed as 25I-NBOMe under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

25I-NBOMe in Thailand, full detail →

2C-B

Legal status: 2C-B is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries 2CB (4-bromo-2,5 dimethoxyphenethylamine) as an entry beneath it. The entry spells the chemistry out as 4-bromo-2,5 dimethoxyphenethylamine beside the short form, so the identification does not rest on the short form alone. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of 2C-B triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. The entry that carries this exposure is printed with its chemistry, 4-bromo-2,5 dimethoxyphenethylamine, so section 145 attaches on the molecule and not on a market abbreviation.
If prescribed / medical: 2C-B sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for 2C-B. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The 2C-E, 2C-I and 2C-T-7 rows in this table did not settle, so a product sold as a 2C compound is answered by this row only if it is the brominated member the table names.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: 2C-B was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check the full chemical name rather than the two character label, because three other 2C compounds appear in this set and every one of them is unresolved. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for 2C-B is printed as 2CB (4-bromo-2,5 dimethoxyphenethylamine) under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

2C-B in Thailand, full detail →

3-MMC

Legal status: 3-MMC is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries 3-methylmethcathinone as an entry beneath it. The entry is the full chemical name rather than the market abbreviation, which is what makes the identification exact. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of 3-MMC triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. The entry that carries this exposure is printed as 3-methylmethcathinone in full, so section 145 follows the written chemical name and not the three letter market abbreviation.
If prescribed / medical: 3-MMC sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for 3-MMC. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Mephedrone, methylone and MDPV are each separately named in the same category while the parent cathinone row in this table is a closed list absence, so this family is reached one name at a time.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: 3-MMC was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check for the written out chemical name on any analysis, because the table carries 3-methylmethcathinone and not the abbreviation a seller would use. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for 3-MMC is printed as 3-methylmethcathinone under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

3-MMC in Thailand, full detail →

7-Hydroxymitragynine (7-OH)

Legal status: Neither 7-hydroxymitragynine nor kratom is separately scheduled in Thailand: 7-OH, a kratom alkaloid, is a constituent of the now-legal plant, decriminalised together with kratom (removed from Category 5 in 2021) and regulated under the Kratom Plant Act B.E. 2565 (2022), with certain sales and uses restricted. [Likely] That finding is carried forward from the entry published before this batch and was not re-derived from statute in this pass. Not confirmed for 7-hydroxymitragynine, and the reason is a reach question that did not settle rather than an absence that did. The search ran in Thai and in Latin script across the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices. The nearest entry it reached was mitragynine, and that was rejected because it is a different molecule and this scheme names molecules rather than families. This is a metabolite question sitting on top of an unresolved parent, so two links in the chain are open rather than one. A second check of the Narcotics Code's salts, derivatives and preparations language and of the Minister's notification power did not establish that 7-hydroxymitragynine is automatically caught, so the exact criminal classification remains open. This is not a finding that 7-hydroxymitragynine is uncontrolled in Thailand, and it is not a finding that the near entry catches it either.
Consequences if caught: Capital exposure: not established. No capital and no life exposure can be stated for 7-hydroxymitragynine and neither can be ruled out, because no category was proved and in this scheme the ceiling follows the placement: with the placement open there is no section 145, 146 or 149 figure to attach. The rejected near entry carries its own exposure and it is not this substance's, since mitragynine is itself unresolved in this table, so the near entry settles nothing. If a later notification placed 7-hydroxymitragynine in Category I, the section 145 paragraph 3 death alternative would still be discretionary and circumstance based, reserved for an organised network leader or a state or public security impact, and never triggered by a stated quantity. Treat the risk as unquantified rather than as low.
If prescribed / medical: No proved schedule placement exists for 7-hydroxymitragynine in this reading, so there is no category to attach a medical or traveller route to. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for 7-hydroxymitragynine. Two things are open at once here, the classification and the permission, and the second cannot be answered before the first. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Neither this compound nor mitragynine is placed, and the kratom row is a closed list absence, so all three links in this chain are unsettled and in different ways.
Documentation: Carry the search record rather than a conclusion: for 7-hydroxymitragynine the sweep covered the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic notices, reached mitragynine as the nearest entry, rejected it as a different molecule, and stopped there. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, unresolved reach question for 7-hydroxymitragynine: searched in Thai and Latin script against the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the B.E. 2565 psychotropic naming notices, with mitragynine recorded as the rejected near entry and the Narcotics Code B.E. 2564 salts, derivatives and preparations language checked without result · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The finding in this cell is carried forward from the entry published before this batch and was not re-derived from statute in this pass · it is tagged [Likely] where it appears. · Updated September 21, 2026

7-Hydroxymitragynine (7-OH) in Thailand, full detail →

Adderall

Legal status: Adderall is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries amphetamine as an entry beneath it. Adderall is resolved as an amphetamine salt preparation and not as a brand name schedule entry, because the table carries active ingredients rather than trade names, so the finding runs through the Category I amphetamine line. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of Adderall triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. The exposure stated here is the amphetamine entry's, because the table carries active ingredients and not trade names, so a brand named tablet is read through what it contains.
If prescribed / medical: A person carrying prescribed Adderall is carrying amphetamine, and amphetamine sits in narcotics Category I on the 15 September 2025 table, so the prescription and the classification point in opposite directions. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Adderall. The foreign prescription was not read here as creating any Thai permission, and nothing in the instruments opened says that it converts into one on arrival. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists.
Documentation: Carry the prescription, the original dispensing packaging and a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and understand what they are up against: the active ingredient is amphetamine, which sits in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Do not assume a foreign prescription becomes a Thai permission at the border. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for Adderall is printed as amphetamine under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Adderall in Thailand, full detail →

Alcohol

Legal status: Alcohol is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Alcohol is the clearest case of a substance regulated hard and regulated elsewhere, and this row says only that the Narcotics Code is not where. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Alcohol is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Alcohol is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Alcohol under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Alcohol is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Alcohol, if any, is not established here. Alcohol is the clearest case in this set of a substance regulated hard and regulated elsewhere, and this row says only that the Narcotics Code is not where.
If prescribed / medical: No entry for Alcohol was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Alcohol is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Alcohol. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Alcohol is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Alcohol is not a prescription question in ordinary use, so what this row leaves unanswered is the excise, licensing and product side rather than a medical route.
Documentation: Carry the distinction this row rests on: the finding for Alcohol is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Take nothing from this row into a customs or duty question, because those run on instruments this reading did not touch. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Alcohol: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Alcohol in Thailand, full detail →

Amanita muscaria

Legal status: Amanita muscaria is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. The mushroom is not named, and neither ibotenic acid nor muscimol was found as a separate entry in what was read. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Amanita muscaria is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Amanita muscaria is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Amanita muscaria under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Amanita muscaria is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Amanita muscaria, if any, is not established here. Neither ibotenic acid nor muscimol was found as a separate entry either, so there is no constituent line in those two instruments carrying an exposure the mushroom itself does not.
If prescribed / medical: No entry for Amanita muscaria was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Amanita muscaria is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Amanita muscaria. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Amanita muscaria is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Psilocybin, the other mushroom constituent this table answers, is a Category 1 psychotropic with a 10 year ceiling, so the two mushrooms in this set are answered by different findings and must not be read together.
Documentation: Carry the distinction this row rests on: the finding for Amanita muscaria is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Take the constituent names, ibotenic acid and muscimol, into any further check, because the sweep looked for them and for the mushroom and returned nothing for any of the three. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Amanita muscaria: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Amanita muscaria in Thailand, full detail →

Amphetamine

Legal status: Amphetamine is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries amphetamine as an entry beneath it. The amphetamine entry is also what this table's Adderall row runs through, while the 6-APB row records amphetamine as a near entry it rejected. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of Amphetamine triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. This same entry is what the Adderall row runs through, so the section 145 exposure stated here reaches a prescribed salt preparation and a street powder alike.
If prescribed / medical: Amphetamine sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Amphetamine. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The 6-APB row in this table rejected amphetamine as a near entry, so a benzofuran analogue is not answered by this placement however much it resembles it.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: Amphetamine was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check whether an analysis names amphetamine itself, because this table reaches Adderall through this entry and leaves 6-APB unresolved. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for Amphetamine is printed as amphetamine under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Amphetamine in Thailand, full detail →

Amyl Nitrite

Legal status: Amyl nitrite is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. This table's poppers row is the label that amyl nitrite is usually sold under, and the two rows have to be read together. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Amyl nitrite is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Amyl nitrite is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Amyl nitrite under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Amyl nitrite is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Amyl nitrite, if any, is not established here. The poppers row in this table is the label amyl nitrite is usually sold under, and the two rows have to be read together, because that row resolves to this one for this constituent and to nothing for the others.
If prescribed / medical: No entry for Amyl nitrite was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Amyl nitrite is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Amyl nitrite. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Amyl nitrite is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. No medical route is in question, and the other alkyl nitrites sold under the same label were not swept individually in this set at all.
Documentation: Carry the distinction this row rests on: the finding for Amyl nitrite is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Use the chemical name rather than the market label, because this set sweeps amyl nitrite and leaves the rest of the alkyl nitrites unswept. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Amyl nitrite: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Amyl Nitrite in Thailand, full detail →

Ayahuasca

Legal status: Ayahuasca is reached through the DMT entry in Thailand's psychotropic Category 1. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 1, psychotropic substances in category 1, and names DMT beneath it. Ayahuasca is not named anywhere in the notification. A DMT containing preparation is reached through the DMT entry, so the brew's status follows its constituent rather than its name. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149(1) provides neither a death penalty nor life imprisonment, and for Ayahuasca that is the end of it: the maximum stated for a Category 1 psychotropic is 10 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. Ayahuasca is not named anywhere in the notification, so the 10 year ceiling stated here is the DMT entry's, reached through the brew's constituent.
If prescribed / medical: Ayahuasca sits in psychotropic Category 1 under the B.E. 2565 naming notification, with a 10 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Ayahuasca. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. A brew that does not contain DMT is not answered by this row at all, because the name carries nothing in this scheme and the constituent carries everything.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Ayahuasca is a Category 1 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check what the preparation contains rather than what it is called, because the notification names DMT and says nothing about the brew. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 10 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 1, where Ayahuasca is reached by the entry for DMT · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Ayahuasca in Thailand, full detail →

Benzodiazepines

Legal status: Not applicable as a class status, and not because the notifications are silent about the members. Benzodiazepines is a class label rather than a single entry, and Thailand's scheme names molecules one at a time: this table answers six of them and they do not land together. Alprazolam and nimetazepam are psychotropic Category 2 under the B.E. 2565 naming notification. Diazepam, clonazepam and lorazepam are psychotropic Category 4 under the same notification. Etizolam is the sixth and it did not settle, because the search rejected alprazolam as a near entry on the ground that it is a different molecule, so its classification is open. Five placements across two categories plus one unresolved reach question cannot be compressed into one status, and those six rows, not this one, carry the placements.
Consequences if caught: Capital exposure: none. Neither a death penalty nor a life term is available for any benzodiazepine this table places, and the class ceiling is two figures rather than one: section 149 states a maximum of 7 years for the Category 2 members, alprazolam and nimetazepam, and 5 years for the Category 4 members, diazepam, clonazepam and lorazepam, with no death penalty, no life imprisonment and no quantity trigger in either. Section 145 paragraph 3, the only limb this dossier records as reaching life or death, governs Category I narcotics, and no benzodiazepine answered here is in Category I. Etizolam carries no stated ceiling at all, because its category was never proved. Any account that puts a Thai capital exposure on a prescribed benzodiazepine has merged the psychotropic categories with the narcotic ones.
If prescribed / medical: A benzodiazepine's position depends on which member is in the packet, so this row cannot state one prescription answer: Category 2 placement carries a different section 149 maximum from Category 4, and etizolam has no proved placement at all. Thailand's country level traveller rule for personal medication was not established by this reading, which opened the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices, none of them for an import permit route, a personal supply quantity ceiling or a certificate requirement. The dossier is explicit that these are naming instruments rather than traveller permit labels, so the permission is what is missing here and not the classification.
Documentation: Carry the member level answer rather than the class: check which benzodiazepine is actually prescribed, read that substance's own row for its category and its section 149 maximum, and note that etizolam has no settled placement to read. Bring the prescription, the original dispensing packaging and a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, treating them as necessary rather than sufficient because no Thai traveller route was established here. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification carrying all five placed members, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, class label resolved member by member: Narcotics Code B.E. 2564 section 94 with penalties at section 149 · Ministry of Public Health psychotropic naming notification B.E. 2565 placing alprazolam and nimetazepam in category 2 and diazepam, clonazepam and lorazepam in category 4, with etizolam unresolved against the same instruments · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026, alongside the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Benzodiazepines in Thailand, full detail →

Buprenorphine

Legal status: Buprenorphine is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. The sweep matched names and not therapeutic classes, so what it establishes is the absence of one name from two documents and not the position of Buprenorphine in Thai law as a whole. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Buprenorphine is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Buprenorphine is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Buprenorphine under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Buprenorphine is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Buprenorphine, if any, is not established here. The sweep matched names and not therapeutic classes, so what it returned is the absence of one name from two documents and it carries nothing about how any other instrument classifies this substance.
If prescribed / medical: No entry for Buprenorphine was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Buprenorphine is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Buprenorphine. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Buprenorphine is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Methadone, the other substitution medicine this table answers, is a named Category II narcotic with no programme exemption recorded, so this set establishes a single settled route for neither of them.
Documentation: Carry the distinction this row rests on: the finding for Buprenorphine is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Use the international non-proprietary name in any further check, because that is the form the sweep ran on and the only form its result covers. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Buprenorphine: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Buprenorphine in Thailand, full detail →

Caffeine

Legal status: Caffeine is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Caffeine is one of the constituents reported under the pink cocaine label, and this row is what that label's row points at for it. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Caffeine is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Caffeine is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Caffeine under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Caffeine is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Caffeine, if any, is not established here. Caffeine is one of the constituents reported under the pink cocaine label and this row is what that label's row points at for it, so one street label in this set resolves to both a closed list absence and three Category I placements.
If prescribed / medical: No entry for Caffeine was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Caffeine is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Caffeine. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Caffeine is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Caffeine is not a prescription question in ordinary use, so what this row leaves unanswered is the food and product side rather than a medical route.
Documentation: Carry the distinction this row rests on: the finding for Caffeine is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Draw no inference from this row to any other constituent of the same street label, because they are answered separately and they do not agree. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Caffeine: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Caffeine in Thailand, full detail →

Cannabinol

Legal status: Controlled as an extract, by the tetrahydrocannabinol content of the preparation rather than by its own name. Cannabinol is not named anywhere in the notification specifying Category 5 narcotics. A cannabinol preparation obtained from cannabis or hemp is an extract, and extracts from every part of those plants are Category 5 narcotics unless one of two narrow exemptions applies. [Likely] That finding is carried forward from the entry published before this batch and was not re-derived from statute in this pass. Not confirmed for Cannabinol, and the reason is a reach question that did not settle rather than an absence that did. The search ran in Thai and in Latin script across the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices. The nearest entry it reached was tetrahydrocannabinol, and that was rejected because it is a different molecule and this scheme names molecules rather than families. CBN is a degradation product of THC and a different molecule from it, and the cannabis extract rules are a separate question from the narcotics table. A second check of the Narcotics Code's salts, derivatives and preparations language and of the Minister's notification power did not establish that Cannabinol is automatically caught, so the exact criminal classification remains open. This is not a finding that Cannabinol is uncontrolled in Thailand, and it is not a finding that the near entry catches it either.
Consequences if caught: Capital exposure: not established. No capital and no life exposure can be stated for Cannabinol and neither can be ruled out, because no category was proved and in this scheme the ceiling follows the placement: with the placement open there is no section 145, 146 or 149 figure to attach. The rejected near entry carries its own exposure and it is not this substance's, since tetrahydrocannabinol is the cannabis constituent the extract rules turn on. If a later notification placed Cannabinol in Category I, the section 145 paragraph 3 death alternative would still be discretionary and circumstance based, reserved for an organised network leader or a state or public security impact, and never triggered by a stated quantity. Treat the risk as unquantified rather than as low.
If prescribed / medical: No proved schedule placement exists for Cannabinol in this reading, so there is no category to attach a medical or traveller route to. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Cannabinol. Two things are open at once here, the classification and the permission, and the second cannot be answered before the first. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The extract route in this set is answered in the CBD row under Category V conditions, and this row was not resolved by it.
Documentation: Carry the search record rather than a conclusion: for Cannabinol the sweep covered the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic notices, reached tetrahydrocannabinol as the nearest entry, rejected it as a different molecule, and stopped there. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, unresolved reach question for Cannabinol: searched in Thai and Latin script against the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the B.E. 2565 psychotropic naming notices, with tetrahydrocannabinol recorded as the rejected near entry and the Narcotics Code B.E. 2564 salts, derivatives and preparations language checked without result · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The finding in this cell is carried forward from the entry published before this batch and was not re-derived from statute in this pass · it is tagged [Likely] where it appears. · Updated September 21, 2026

Cannabinol in Thailand, full detail →

Cannabis / THC

Legal status: Cannabis in Thailand is a controlled herb, and that is neither the 2022 position nor a return to the narcotics list. The Department of Thai Traditional and Alternative Medicine's Controlled Herb (Cannabis) Notification B.E. 2568, effective 26 June 2025, repealed and replaced the 2022 controlled herb notice, and it makes เฉพาะส่วนของช่อดอก, only the inflorescence, the controlled part. Cannabis had left the ordinary narcotics list in 2022 except for non-exempt extracts, and on the research date the flower had not simply come back as Category V plant material: it sits on the controlled herb route, restricted to the statutory licence and medical prescription channel, while qualifying extracts remain a separate Category V question answered in this table's CBD row. The governing instrument here is the Traditional Thai Medical Wisdom Protection Act rather than the Narcotics Code, which is why this row's penalties look unlike every other row in the table. Nothing about this position generalises to any other substance listed here.
Consequences if caught: Capital exposure: none. Neither a death penalty nor a life term appears anywhere in this row, and the distance between cannabis and the rest of the table is the point: a controlled herb violation can reach 1 year of imprisonment and a 20,000 baht fine, while a Category V extract falls under Narcotics Code section 148, which allows up to 5 years, or 1 to 15 years in aggravated trafficking cases, with no death penalty at all. The 2022 recreational description that English accounts still repeat was not current on the research date. Treating flower as freely tradeable is the specific error this row exists to correct, because the licensed and prescribed route is now the lawful one and supply outside it is not.
If prescribed / medical: Cannabis is the one row in this table where the dossier does establish a route. Under the B.E. 2568 notification in force from 26 June 2025, flower supply runs through the statutory licence and the medical prescription channel, so a prescription is central here in a way it is not elsewhere in this table. That route is a domestic supply rule and it is not a traveller rule: this reading did not establish whether a foreign prescription is recognised, whether an import permit exists, or what personal quantity a traveller may carry, and the 2026 implementation forms were noted rather than read for that purpose. Extracts are a separate question again, governed by the Category V conditions and the THC limits rather than by the controlled herb notification.
Documentation: Carry the Thai prescription and the licence documentation for the supply route, and treat any foreign paperwork as unestablished: the B.E. 2568 notification is what makes flower a controlled herb on a licensed and prescribed channel, and it was not read as recognising a foreign prescription or as setting a traveller allowance. Do not carry the 2022 description of Thai cannabis law, which is the single most repeated error about this country. The reading was taken on 20 September 2026 from the Department of Thai Traditional and Alternative Medicine's publication of the Controlled Herb (Cannabis) Notification B.E. 2568, at https://www.dtam.moph.go.th/sub-law/42864/. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link.

Thailand, Controlled Herb (Cannabis) Notification B.E. 2568 made under the Traditional Thai Medical Wisdom Protection Act, effective 26 June 2025 and repealing the 2022 controlled herb notice, with the controlled part given as เฉพาะส่วนของช่อดอก, only the inflorescence · controlled herb violations reaching 1 year and a 20,000 baht fine, with non-exempt extracts falling to Narcotics Code B.E. 2564 section 148 · read at https://www.dtam.moph.go.th/sub-law/42864/ on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Cannabis / THC in Thailand, full detail →

Cathinone

Legal status: Cathinone is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. The parent cathinone returned no entry while mephedrone, 3-MMC, methylone and MDPV are each named in Category I, which is the closed list working exactly as described: derivatives are reached by being named, not by their parent. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Cathinone is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Cathinone is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Cathinone under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Cathinone is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Cathinone, if any, is not established here. Mephedrone, 3-MMC, methylone and MDPV are each named in Category I under section 145 while the parent returned nothing, so the exposure sits on the named derivatives and not on the family.
If prescribed / medical: No entry for Cathinone was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Cathinone is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Cathinone. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Cathinone is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The khat row in this table returned no entry for the leaf either, so neither the alkaloid nor the plant that carries it is placed while four of its derivatives are.
Documentation: Carry the distinction this row rests on: the finding for Cathinone is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Take the derivative names separately, because in this table being a cathinone is not what reaches a compound and being named is. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Cathinone: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Cathinone in Thailand, full detail →

CBD

Legal status: CBD is not answered in Thailand by the label on the bottle. The Ministry of Public Health Category V notification B.E. 2565 covers สารสกัดจากทุกส่วนของพืชกัญชา, extracts from every part of the cannabis plant, subject to that notification's own exceptions and its THC conditions, and the Controlled Herb (Cannabis) Notification B.E. 2568 sits alongside it for the plant material. So the status of a given CBD product turns on whether the extract qualifies for the exemption and on what it contains, and a qualifying low-THC exempt extract and a non-qualifying Category V cannabis extract take different routes under the same name. This row therefore states a test rather than a single terminal placement, because the instrument itself is written that way.
Consequences if caught: Capital exposure: none. Neither a death penalty nor a life term is reachable on this row: a non-exempt Category V cannabis extract is subject to Narcotics Code section 148, which allows up to 5 years, or 1 to 15 years in aggravated cases, and Category V carries no death penalty and no life term. A qualifying exempt extract does not enter that penalty structure at all, which is why the THC condition does more work here than any quantity of product does. Section 145 paragraph 3 and its capital alternative belong to Category I narcotics and have nothing to do with a cannabis extract.
If prescribed / medical: A CBD product's route depends on which side of the exemption the extract falls, and this reading establishes that fork rather than a single answer: a qualifying low-THC exempt extract and a non-qualifying Category V extract are treated differently under the B.E. 2565 notification, while the plant material itself runs on the separate controlled herb channel. Thailand's country level traveller rule was not established here for either side of that fork, so no import permit, personal quantity allowance or certificate requirement for a CBD product can be stated from what was read. A product bought lawfully elsewhere is not thereby a qualifying extract in Thailand, because the qualification is defined by the Thai notification's own conditions.
Documentation: Carry the certificate of analysis showing the THC content, not just the CBD label, because the exemption in the B.E. 2565 notification runs on the composition and the notification's stated conditions rather than on the marketing name. Nothing read here establishes that such a certificate is accepted at the Thai border, so treat it as the minimum rather than as the answer. The reading was taken on 20 September 2026 from the consolidated narcotics table carrying the Category V position, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf, read with the Controlled Herb (Cannabis) Notification B.E. 2568. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link.

Thailand, Ministry of Public Health Category V notification B.E. 2565 covering extracts from every part of the cannabis plant subject to its exceptions and THC conditions, read with the Controlled Herb (Cannabis) Notification B.E. 2568 · penalties for a non-exempt Category V extract at Narcotics Code B.E. 2564 section 148, up to 5 years or 1 to 15 years in aggravated cases · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

CBD in Thailand, full detail →

Clonazepam

Legal status: Clonazepam is a Category 4 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 4, psychotropic substances in category 4, and names clonazepam beneath it. Clonazepam sits in Category 4 with diazepam and lorazepam, one category below alprazolam and nimetazepam. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for Clonazepam that is the end of it: the maximum stated for a Category 4 psychotropic is 5 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. Clonazepam sits in Category 4 with diazepam and lorazepam and one category below alprazolam and nimetazepam, so the 5 year figure is the lower of the two ceilings this notification gives the benzodiazepines in this set.
If prescribed / medical: Clonazepam sits in psychotropic Category 4 under the B.E. 2565 naming notification, with a 5 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Clonazepam. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The category and not the class is what sets the ceiling, and three of the six benzodiazepines this table answers land here.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Clonazepam is a Category 4 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check the individual name, because this notification puts clonazepam in Category 4 and alprazolam in Category 2. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 5 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 4, where Clonazepam is reached by the entry for clonazepam · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Clonazepam in Thailand, full detail →

Cocaine

Legal status: Cocaine is a Category II narcotic in Thailand. The Thai FDA table updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 2, narcotics subject to penalty of category 2, and names cocaine beneath it. The crack form is not given a line of its own; this table's crack cocaine row runs through this same cocaine entry. Section 91 of the Narcotics Code B.E. 2564 is the Category II limb and section 146 carries its penalties, while the identity again comes from a Ministry of Public Health notification rather than from the Code. Category II is a different place in this scheme from Category I, and the difference is not cosmetic: it changes which penalty section applies and removes the limb that can reach life or death.
Consequences if caught: Capital exposure: none. Section 146 carries no death penalty and no life term at all, and that is the first thing to say about Cocaine. The ceiling it states is up to 10 years, rising to 1 to 15 years where the Category II conduct is commerce or public dissemination. Section 145 paragraph 3, the only limb this dossier records as reaching life or death, governs Category I narcotics and does not follow a Category II substance. No quantity threshold is written into the section 146 penalty limb either, so weight is not what moves a case between those two bands. The crack form is not given a line of its own, so the section 146 exposure stated here is also what this table's crack cocaine row runs through.
If prescribed / medical: Cocaine sits in narcotics Category II under the 15 September 2025 table, and the placement is the classification rather than a statement about who may lawfully hold it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Cocaine. A prescription does not move the entry out of Category II, and the route that a prescription or a foreign dispensing record would have to satisfy at the Thai border is precisely what was not read. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. A prescription does not move the entry out of Category II, and the crack cocaine row is answered by this same line rather than by one of its own.
Documentation: Carry no expectation that paperwork answers this row, because Cocaine is not something a traveller is dispensed: what was established is a Category II placement in the Thai FDA table updated 15 September 2025, which is a criminal classification and not a permit question, and no Thai exemption or allowance for it was established here. Check that the finding being relied on is this cocaine entry, because the table carries no separate crack line to point at. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 91 with the penalties at section 146 · Ministry of Public Health Category II naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where Cocaine is reached by the entry printed as cocaine under the category 2 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Cocaine in Thailand, full detail →

Codeine

Legal status: Codeine is a Category II narcotic in Thailand. The Thai FDA table updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 2, narcotics subject to penalty of category 2, and names codeine beneath it. Codeine sits in Category II rather than in the Category I limb that holds heroin, even though both are opiates. Section 91 of the Narcotics Code B.E. 2564 is the Category II limb and section 146 carries its penalties, while the identity again comes from a Ministry of Public Health notification rather than from the Code. Category II is a different place in this scheme from Category I, and the difference is not cosmetic: it changes which penalty section applies and removes the limb that can reach life or death.
Consequences if caught: Capital exposure: none. Section 146 carries no death penalty and no life term at all, and that is the first thing to say about Codeine. The ceiling it states is up to 10 years, rising to 1 to 15 years where the Category II conduct is commerce or public dissemination. Section 145 paragraph 3, the only limb this dossier records as reaching life or death, governs Category I narcotics and does not follow a Category II substance. No quantity threshold is written into the section 146 penalty limb either, so weight is not what moves a case between those two bands. Codeine sits in Category II under section 146 while heroin sits in Category I under section 145, even though both are opiates, so this family does not share one ceiling.
If prescribed / medical: Codeine sits in narcotics Category II under the 15 September 2025 table, and the placement is the classification rather than a statement about who may lawfully hold it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Codeine. A prescription does not move the entry out of Category II, and the route that a prescription or a foreign dispensing record would have to satisfy at the Thai border is precisely what was not read. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is an opiate the table places with the medical ones rather than with heroin, and that split is the difference a reader should carry.
Documentation: Carry the prescription, the original dispensing packaging and a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and treat them as necessary rather than sufficient: this reading establishes only that Codeine is a Category II narcotic in the table updated 15 September 2025, and it does not establish what those papers achieve at a Thai port of entry. Check which category the named opiate falls in, because this table splits them between sections 146 and 145. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 91 with the penalties at section 146 · Ministry of Public Health Category II naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where Codeine is reached by the entry printed as codeine under the category 2 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Codeine in Thailand, full detail →

Crack Cocaine

Legal status: Crack cocaine is a Category II narcotic in Thailand. The Thai FDA table updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 2, narcotics subject to penalty of category 2, and names cocaine beneath it. Crack is treated as the cocaine form rather than as a separate entry, so the table's cocaine line is what reaches it and there is no crack line to find. Section 91 of the Narcotics Code B.E. 2564 is the Category II limb and section 146 carries its penalties, while the identity again comes from a Ministry of Public Health notification rather than from the Code. Category II is a different place in this scheme from Category I, and the difference is not cosmetic: it changes which penalty section applies and removes the limb that can reach life or death.
Consequences if caught: Capital exposure: none. Section 146 carries no death penalty and no life term at all, and that is the first thing to say about Crack cocaine. The ceiling it states is up to 10 years, rising to 1 to 15 years where the Category II conduct is commerce or public dissemination. Section 145 paragraph 3, the only limb this dossier records as reaching life or death, governs Category I narcotics and does not follow a Category II substance. No quantity threshold is written into the section 146 penalty limb either, so weight is not what moves a case between those two bands. There is no crack line in the table to carry an exposure of its own, so the section 146 figures stated here are the cocaine entry's, reached through the form.
If prescribed / medical: Crack cocaine sits in narcotics Category II under the 15 September 2025 table, and the placement is the classification rather than a statement about who may lawfully hold it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Crack cocaine. A prescription does not move the entry out of Category II, and the route that a prescription or a foreign dispensing record would have to satisfy at the Thai border is precisely what was not read. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The absence of a separate entry is a finding about the table's drafting rather than about the product, and it means this row and the cocaine row cannot diverge.
Documentation: Carry no expectation that paperwork answers this row, because Crack cocaine is not something a traveller is dispensed: what was established is a Category II placement in the Thai FDA table updated 15 September 2025, which is a criminal classification and not a permit question, and no Thai exemption or allowance for it was established here. Check the cocaine entry itself, because crack is treated as the cocaine form and the table has nothing else to point at. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 91 with the penalties at section 146 · Ministry of Public Health Category II naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where Crack cocaine is reached by the entry printed as cocaine under the category 2 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Crack Cocaine in Thailand, full detail →

Delta-8-THC

Legal status: Controlled by THC content, under the Narcotics Code (B.E. 2564) and the 2022 cannabis reform, any cannabis/hemp EXTRACT containing more than 0.2% tetrahydrocannabinol by weight remains a Category 5 narcotic; delta-8-THC (Δ8-THC) is caught as a tetrahydrocannabinol above that threshold, controlled by its THC content rather than named. Distinct from cannabis buds/plant, largely decriminalised post-2022 subject to tightening rules. No death penalty. [Likely] That finding is carried forward from the entry published before this batch and was not re-derived from statute in this pass. Not confirmed for Delta-8-THC, and the reason is a reach question that did not settle rather than an absence that did. The search ran in Thai and in Latin script across the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices. The nearest entry it reached was tetrahydrocannabinol, and that was rejected because it is a different molecule and this scheme names molecules rather than families. A double bond in a different position is a different isomer, and the table was not read as naming the isomers generically. A second check of the Narcotics Code's salts, derivatives and preparations language and of the Minister's notification power did not establish that Delta-8-THC is automatically caught, so the exact criminal classification remains open. This is not a finding that Delta-8-THC is uncontrolled in Thailand, and it is not a finding that the near entry catches it either.
Consequences if caught: Capital exposure: not established. No capital and no life exposure can be stated for Delta-8-THC and neither can be ruled out, because no category was proved and in this scheme the ceiling follows the placement: with the placement open there is no section 145, 146 or 149 figure to attach. The rejected near entry carries its own exposure and it is not this substance's, since tetrahydrocannabinol is the cannabis constituent the extract rules turn on. If a later notification placed Delta-8-THC in Category I, the section 145 paragraph 3 death alternative would still be discretionary and circumstance based, reserved for an organised network leader or a state or public security impact, and never triggered by a stated quantity. Treat the risk as unquantified rather than as low. A double bond in a different position is a different isomer, and the table was not read as naming the isomers generically, so the exposure the named cannabinoid carries is not available to state here.
If prescribed / medical: No proved schedule placement exists for Delta-8-THC in this reading, so there is no category to attach a medical or traveller route to. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Delta-8-THC. Two things are open at once here, the classification and the permission, and the second cannot be answered before the first. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The cannabis and CBD rows in this set run on the extract and controlled herb instruments rather than on the narcotics table, and neither was read as answering this isomer.
Documentation: Carry the search record rather than a conclusion: for Delta-8-THC the sweep covered the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic notices, reached tetrahydrocannabinol as the nearest entry, rejected it as a different molecule, and stopped there. Check which isomer is named in any instrument relied on, because the table was not read as naming them generically. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, unresolved reach question for Delta-8-THC: searched in Thai and Latin script against the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the B.E. 2565 psychotropic naming notices, with tetrahydrocannabinol recorded as the rejected near entry and the Narcotics Code B.E. 2564 salts, derivatives and preparations language checked without result · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The finding in this cell is carried forward from the entry published before this batch and was not re-derived from statute in this pass · it is tagged [Likely] where it appears. · Updated September 21, 2026

Delta-8-THC in Thailand, full detail →

Diazepam

Legal status: Diazepam is a Category 4 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 4, psychotropic substances in category 4, and names diazepam beneath it. The placement is psychotropic and it is nothing more than that. English accounts that merge the psychotropic categories with the narcotic ones put a Narcotics Code capital exposure on prescribed diazepam, and that is simply wrong. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for Diazepam that is the end of it: the maximum stated for a Category 4 psychotropic is 5 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. English accounts that merge the psychotropic categories with the narcotic ones put a Narcotics Code capital exposure on prescribed diazepam, and that is simply wrong: the placement is psychotropic and nothing more.
If prescribed / medical: Diazepam sits in psychotropic Category 4 under the B.E. 2565 naming notification, with a 5 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Diazepam. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is the row where the merged category error does the most damage, because it is the most widely prescribed of the six benzodiazepines this table answers.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Diazepam is a Category 4 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check that any warning being relied on names the psychotropic category, because the capital exposure attached to this medicine in English accounts belongs to a different limb of the Code. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 5 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 4, where Diazepam is reached by the entry for diazepam · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Diazepam in Thailand, full detail →

DMT

Legal status: DMT is a Category 1 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 1, psychotropic substances in category 1, and names DMT beneath it. The DMT entry is also what this table's ayahuasca row runs through, and it is the near entry that the 4-AcO-DMT, 4-HO-MET and 5-MeO-DMT rows each rejected as a different molecule. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for DMT that is the end of it: the maximum stated for a Category 1 psychotropic is 10 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. This same entry is what the ayahuasca row runs through, and it is the near entry that the 4-AcO-DMT, 4-HO-MET and 5-MeO-DMT rows each rejected, so the 10 year ceiling reaches the preparation and not those analogues.
If prescribed / medical: DMT sits in psychotropic Category 1 under the B.E. 2565 naming notification, with a 10 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for DMT. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. A preparation containing DMT is reached by this entry even when it is not named, which is how the ayahuasca row is answered, while three tryptamine rows in this table remain open.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for DMT is a Category 1 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check whether a preparation contains DMT itself, because this entry reaches the brew and not the three analogues this set leaves unresolved. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 10 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 1, where DMT is reached by the entry for DMT · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

DMT in Thailand, full detail →

DOM

Legal status: DOM is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries STP / DOM as an entry beneath it. The entry is printed as a pair, the older research name STP beside DOM, and both point at the one molecule. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of DOM triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. The entry that carries this exposure is printed as a pair, the older research name STP beside DOM, so section 145 attaches whichever of the two names appears.
If prescribed / medical: DOM sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for DOM. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Neither name is a medicine anywhere in this table, and the pairing in the entry is a naming convention rather than two separate placements.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: DOM was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check for either name, because the table prints STP and DOM on one line and both point at the one molecule. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for DOM is printed as STP / DOM under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

DOM in Thailand, full detail →

DXM

Legal status: DXM is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Dextromethorphan returned no entry in the narcotics table or the psychotropic notices, which is a schedule finding and not a statement about how it is sold. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that DXM is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches DXM is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for DXM under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that DXM is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches DXM, if any, is not established here. Dextromethorphan returned no entry in either instrument, which is a schedule finding and not a statement about how it is sold, so the section 149 dissociative ceilings in this table are not this row's figures and neither is any other.
If prescribed / medical: No entry for DXM was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that DXM is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for DXM. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether DXM is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is an over the counter preparation in many countries, and the tier that governs that in Thailand is precisely what was not read.
Documentation: Carry the distinction this row rests on: the finding for DXM is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Search the full name dextromethorphan as well as the abbreviation, because a three letter market label is not the form an instrument would name. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for DXM: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

DXM in Thailand, full detail →

Ephedrine

Legal status: Ephedrine is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Ephedrine returned no entry as a scheduled substance, and precursor controls sit outside the notifications that were read here. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Ephedrine is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Ephedrine is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Ephedrine under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Ephedrine is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Ephedrine, if any, is not established here. Precursor controls sit outside the two notifications that were read here, and methamphetamine, which this table places in Category I under section 145, is not what gives this row a figure.
If prescribed / medical: No entry for Ephedrine was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Ephedrine is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Ephedrine. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Ephedrine is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. An over the counter decongestant and a precursor are two different questions, and this reading answered neither of them.
Documentation: Carry the distinction this row rests on: the finding for Ephedrine is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Treat the precursor question separately, because the instruments read here are narcotic and psychotropic naming notifications and not a precursor schedule. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Ephedrine: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Ephedrine in Thailand, full detail →

Etizolam

Legal status: Etizolam is a Category 4 psychotropic under the Narcotics Code; it is not FDA-registered as a medicine in Thailand. [Likely] That finding is carried forward from the entry published before this batch and was not re-derived from statute in this pass. Not confirmed for Etizolam, and the reason is a reach question that did not settle rather than an absence that did. The search ran in Thai and in Latin script across the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices. The nearest entry it reached was alprazolam, and that was rejected because it is a different molecule and this scheme names molecules rather than families. A thienotriazolodiazepine is not a benzodiazepine by ring structure, so even the class argument is weaker here than it looks. A second check of the Narcotics Code's salts, derivatives and preparations language and of the Minister's notification power did not establish that Etizolam is automatically caught, so the exact criminal classification remains open. This is not a finding that Etizolam is uncontrolled in Thailand, and it is not a finding that the near entry catches it either.
Consequences if caught: Capital exposure: not established. No capital and no life exposure can be stated for Etizolam and neither can be ruled out, because no category was proved and in this scheme the ceiling follows the placement: with the placement open there is no section 145, 146 or 149 figure to attach. The rejected near entry carries its own exposure and it is not this substance's, since alprazolam is a Category 2 psychotropic in this table, with a 7 year section 149 maximum. If a later notification placed Etizolam in Category I, the section 145 paragraph 3 death alternative would still be discretionary and circumstance based, reserved for an organised network leader or a state or public security impact, and never triggered by a stated quantity. Treat the risk as unquantified rather than as low.
If prescribed / medical: No proved schedule placement exists for Etizolam in this reading, so there is no category to attach a medical or traveller route to. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Etizolam. Two things are open at once here, the classification and the permission, and the second cannot be answered before the first. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Five benzodiazepines in this table are placed across two categories while this row is the sixth and is open, which is why the class row in this set states no status.
Documentation: Carry the search record rather than a conclusion: for Etizolam the sweep covered the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic notices, reached alprazolam as the nearest entry, rejected it as a different molecule, and stopped there. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, unresolved reach question for Etizolam: searched in Thai and Latin script against the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the B.E. 2565 psychotropic naming notices, with alprazolam recorded as the rejected near entry and the Narcotics Code B.E. 2564 salts, derivatives and preparations language checked without result · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The finding in this cell is carried forward from the entry published before this batch and was not re-derived from statute in this pass · it is tagged [Likely] where it appears. · Updated September 21, 2026

Etizolam in Thailand, full detail →

Fentanyl

Legal status: Fentanyl is a Category II narcotic in Thailand. The Thai FDA table updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 2, narcotics subject to penalty of category 2, and names fentanyl beneath it. Fentanyl is named as the parent molecule; the table was not read here for any separate analogue line. Section 91 of the Narcotics Code B.E. 2564 is the Category II limb and section 146 carries its penalties, while the identity again comes from a Ministry of Public Health notification rather than from the Code. Category II is a different place in this scheme from Category I, and the difference is not cosmetic: it changes which penalty section applies and removes the limb that can reach life or death.
Consequences if caught: Capital exposure: none. Section 146 carries no death penalty and no life term at all, and that is the first thing to say about Fentanyl. The ceiling it states is up to 10 years, rising to 1 to 15 years where the Category II conduct is commerce or public dissemination. Section 145 paragraph 3, the only limb this dossier records as reaching life or death, governs Category I narcotics and does not follow a Category II substance. No quantity threshold is written into the section 146 penalty limb either, so weight is not what moves a case between those two bands. Fentanyl is named as the parent molecule and the table was not read here for any separate analogue line, so the section 146 exposure stated is the parent's only.
If prescribed / medical: Fentanyl sits in narcotics Category II under the 15 September 2025 table, and the placement is the classification rather than a statement about who may lawfully hold it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Fentanyl. A prescription does not move the entry out of Category II, and the route that a prescription or a foreign dispensing record would have to satisfy at the Thai border is precisely what was not read. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. An analogue is not answered by this row, and this reading did not establish whether the table names any analogue at all.
Documentation: Carry the prescription, the original dispensing packaging and a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and treat them as necessary rather than sufficient: this reading establishes only that Fentanyl is a Category II narcotic in the table updated 15 September 2025, and it does not establish what those papers achieve at a Thai port of entry. Check whether an analysis names fentanyl itself or an analogue, because only the parent entry was read in this table. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 91 with the penalties at section 146 · Ministry of Public Health Category II naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where Fentanyl is reached by the entry printed as fentanyl under the category 2 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Fentanyl in Thailand, full detail →

Gabapentin

Legal status: Gabapentin is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Gabapentin returned no entry, as did pregabalin, so the two gabapentinoids this table answers are in the same position. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Gabapentin is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Gabapentin is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Gabapentin under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Gabapentin is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Gabapentin, if any, is not established here. Pregabalin returned no entry in the same sweep, so the two gabapentinoids this table answers share this position and neither has a Code section to state a figure from.
If prescribed / medical: No entry for Gabapentin was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Gabapentin is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Gabapentin. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Gabapentin is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The phenibut row in this set is a third absence in the same neighbourhood, so three related compounds here are answered the same way and none of them is answered fully.
Documentation: Carry the distinction this row rests on: the finding for Gabapentin is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Read the pregabalin result alongside this one, because the two rows were swept the same way and returned the same thing. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Gabapentin: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Gabapentin in Thailand, full detail →

GBL

Legal status: GBL is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. GBL returned no entry, and neither did GHB, so the pair this table answers is consistent under what was read. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that GBL is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches GBL is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for GBL under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that GBL is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches GBL, if any, is not established here. GHB returned no entry in the same sweep, so the pair this table answers is consistent under what was read, and consistency between two absences is not confirmation of either.
If prescribed / medical: No entry for GBL was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that GBL is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for GBL. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether GBL is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. GBL is an industrial solvent as well as a precursor, and neither of those routes is a narcotic or a psychotropic naming notification.
Documentation: Carry the distinction this row rests on: the finding for GBL is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Read the GHB result alongside this one, because the two rows stand or fall together under what was read. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for GBL: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

GBL in Thailand, full detail →

GHB

Legal status: GHB is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. A closed list absence is a statement about two documents on one date, and this row is that and no more. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that GHB is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches GHB is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for GHB under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that GHB is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches GHB, if any, is not established here. A closed list absence is a statement about two documents on one date, and this row is that and no more, so the missing section 145 or 149 figure is not a finding that no figure exists.
If prescribed / medical: No entry for GHB was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that GHB is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for GHB. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether GHB is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. GBL, its precursor, returned the same absence in the same sweep, so neither row in that pair has been tested against any instrument outside those two.
Documentation: Carry the distinction this row rests on: the finding for GHB is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Keep the date attached to the finding, because this is a two document result taken on 20 September 2026 and a ministerial notification is what moves it. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for GHB: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

GHB in Thailand, full detail →

Heroin

Legal status: Heroin is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries heroin as an entry beneath it. Heroin sits in Category I while morphine and opium sit in Category II in the same table, so the opiate family is split across two categories and two penalty sections. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of Heroin triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. Morphine and opium sit in Category II in this same table under section 146, so the opiate family is split across two penalty sections and this row is on the heavier one.
If prescribed / medical: Heroin sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Heroin. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. No medical route is in question here, and the split from morphine is what makes this row's exposure unlike the rest of the opiates this table answers.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: Heroin was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check which opiate is named, because this table places heroin under section 145 and morphine and opium under section 146. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for Heroin is printed as heroin under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Heroin in Thailand, full detail →

Hydrocodone

Legal status: Hydrocodone is a Category II narcotic in Thailand. The Thai FDA table updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 2, narcotics subject to penalty of category 2, and names hydrocodone beneath it. Hydrocodone is named individually rather than being read out of the codeine or morphine entries. Section 91 of the Narcotics Code B.E. 2564 is the Category II limb and section 146 carries its penalties, while the identity again comes from a Ministry of Public Health notification rather than from the Code. Category II is a different place in this scheme from Category I, and the difference is not cosmetic: it changes which penalty section applies and removes the limb that can reach life or death.
Consequences if caught: Capital exposure: none. Section 146 carries no death penalty and no life term at all, and that is the first thing to say about Hydrocodone. The ceiling it states is up to 10 years, rising to 1 to 15 years where the Category II conduct is commerce or public dissemination. Section 145 paragraph 3, the only limb this dossier records as reaching life or death, governs Category I narcotics and does not follow a Category II substance. No quantity threshold is written into the section 146 penalty limb either, so weight is not what moves a case between those two bands. Hydrocodone is named individually rather than being read out of the codeine or morphine entries, so section 146 attaches to it directly.
If prescribed / medical: Hydrocodone sits in narcotics Category II under the 15 September 2025 table, and the placement is the classification rather than a statement about who may lawfully hold it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Hydrocodone. A prescription does not move the entry out of Category II, and the route that a prescription or a foreign dispensing record would have to satisfy at the Thai border is precisely what was not read. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The individual naming is what makes this row answerable at all, because a derivative argument would not have settled it in this scheme.
Documentation: Carry the prescription, the original dispensing packaging and a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and treat them as necessary rather than sufficient: this reading establishes only that Hydrocodone is a Category II narcotic in the table updated 15 September 2025, and it does not establish what those papers achieve at a Thai port of entry. Check for the individual name on the dispensing label, because this table does not reach hydrocodone through codeine or morphine. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 91 with the penalties at section 146 · Ministry of Public Health Category II naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where Hydrocodone is reached by the entry printed as hydrocodone under the category 2 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Hydrocodone in Thailand, full detail →

Ketamine

Legal status: Ketamine is a Category 2 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 2, psychotropic substances in category 2, and names ketamine beneath it. This table's 2-FDCK and MXE rows each record ketamine as the near entry they rejected, so the placement reaches this molecule and not its analogues. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for Ketamine that is the end of it: the maximum stated for a Category 2 psychotropic is 7 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. The 2-FDCK and MXE rows in this table each rejected ketamine as a near entry, so the 7 year section 149 ceiling stated here reaches this molecule and not its analogues.
If prescribed / medical: Ketamine sits in psychotropic Category 2 under the B.E. 2565 naming notification, with a 7 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Ketamine. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. A veterinary or anaesthetic supply is not a separate entry here, and two analogue rows in this set did not settle at all.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Ketamine is a Category 2 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check that an analysis names ketamine itself, because the 2-FDCK and MXE rows in this set are both unresolved. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 7 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 2, where Ketamine is reached by the entry for ketamine · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Ketamine in Thailand, full detail →

Khat

Legal status: Khat is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Khat returned no entry as a plant, and this table's cathinone row returned none for the alkaloid either. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Khat is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Khat is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Khat under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Khat is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Khat, if any, is not established here. The cathinone row in this table returned no entry for the alkaloid either, so neither the leaf nor its alkaloid is placed while four cathinone derivatives in this same table are named in Category I.
If prescribed / medical: No entry for Khat was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Khat is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Khat. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Khat is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Khat is a leaf chewed rather than a dispensed medicine, so what this row leaves unanswered is the plant, food and import side rather than a prescription route.
Documentation: Carry the distinction this row rests on: the finding for Khat is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Search both names, the plant and the alkaloid, because this set sweeps them in separate rows and returns the same absence for each. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Khat: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Khat in Thailand, full detail →

Kratom

Legal status: Kratom is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. This table's mitragynine row records Kratom as a near entry it found and rejected, and a rejected near entry is normally an entry that exists, which is hard to square with a closed list absence for the leaf itself; the two rows are left in tension and that contradiction is unresolved here rather than settled by picking a side. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Kratom is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Kratom is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Kratom under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Kratom is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Kratom, if any, is not established here. The mitragynine row in this table records kratom as the near entry it rejected, which does not sit easily with a closed list absence for the leaf itself, so this result is in tension with its own neighbour rather than clean.
If prescribed / medical: No entry for Kratom was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Kratom is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Kratom. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Kratom is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Thailand's own treatment of this leaf has changed more than once and none of that history was read here, so the absence is from two documents and not from the record.
Documentation: Carry the distinction this row rests on: the finding for Kratom is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Carry the tension rather than the conclusion, because the alkaloid row names this leaf as an entry it found and rejected while this row reports the leaf as unlisted. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Kratom: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Kratom in Thailand, full detail →

Lorazepam

Legal status: Lorazepam is a Category 4 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 4, psychotropic substances in category 4, and names lorazepam beneath it. Lorazepam is named individually in Category 4, so its placement does not depend on being read as a benzodiazepine class member. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for Lorazepam that is the end of it: the maximum stated for a Category 4 psychotropic is 5 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. Lorazepam is named individually in Category 4, so the 5 year ceiling stated here does not depend on reading it as a benzodiazepine class member.
If prescribed / medical: Lorazepam sits in psychotropic Category 4 under the B.E. 2565 naming notification, with a 5 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Lorazepam. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The individual naming is what settles this row, and the class label would not have reached it in a scheme that names molecules.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Lorazepam is a Category 4 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check for the individual name in the notification, because the class label is not what places this medicine. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 5 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 4, where Lorazepam is reached by the entry for lorazepam · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Lorazepam in Thailand, full detail →

LSD

Legal status: LSD is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries LSD as an entry beneath it. This table's 1P-LSD and LSA rows record LSD as the near entry they rejected, so the Category I placement reaches this molecule and not its neighbours. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of LSD triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. The 1P-LSD and LSA rows in this table each rejected LSD as a near entry, so the section 145 exposure stated here reaches this molecule and not its neighbours.
If prescribed / medical: LSD sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for LSD. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. A blotter is answered by what it analyses as, and two lysergamide rows in this set did not settle, so this placement does not carry across to them.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: LSD was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check the analysis for LSD itself, because the 1P-LSD and LSA rows in this set are both unresolved. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for LSD is printed as LSD under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

LSD in Thailand, full detail →

MDA

Legal status: MDA is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries MDA as an entry beneath it. MDA is named in its own right rather than being read out of the MDMA entry. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of MDA triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. MDA is named in its own right rather than read out of the MDMA entry, so section 145 attaches to it directly and not by derivation.
If prescribed / medical: MDA sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for MDA. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The separate naming matters here, because a scheme that names molecules one at a time would otherwise have left this compound to an argument from resemblance.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: MDA was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check whether an analysis names MDA or MDMA, because the table carries both and neither is read out of the other. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for MDA is printed as MDA under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

MDA in Thailand, full detail →

MDMA

Legal status: MDMA is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries MDMA as an entry beneath it. This row answers the molecule; a powder sold as ecstasy or under the pink cocaine label is answered by whatever it analyses as. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of MDMA triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. A powder sold as ecstasy or under the pink cocaine label is answered by whatever it analyses as, so the section 145 exposure stated here follows the molecule and not the name on the bag.
If prescribed / medical: MDMA sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for MDMA. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The pink cocaine row in this table points at this row for one reported constituent and at ketamine, methamphetamine, 2C-B and caffeine for others, and those do not share this placement.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: MDMA was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check the analysis rather than the street name, because the pink cocaine row in this set resolves to five different findings depending on content. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for MDMA is printed as MDMA under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

MDMA in Thailand, full detail →

MDPV

Legal status: MDPV is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries MDPV as an entry beneath it. MDPV is named in its own right, alongside the other cathinone derivatives the table carries. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of MDPV triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. MDPV is named alongside the other cathinone derivatives this table carries while the parent cathinone row is a closed list absence, so the exposure comes from being named and not from the family.
If prescribed / medical: MDPV sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for MDPV. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Nothing about this placement is medical, and the cathinone row is what shows that the family name is not what reaches it.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: MDPV was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check for the individual name, because in this table a cathinone derivative is reached by being listed and the parent is not listed at all. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for MDPV is printed as MDPV under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

MDPV in Thailand, full detail →

Memantine

Legal status: Memantine is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Memantine returned no entry, and the ketamine placement in the psychotropic notification does not carry across to it. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Memantine is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Memantine is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Memantine under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Memantine is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Memantine, if any, is not established here. The ketamine placement in the psychotropic notification does not carry across to memantine, so the 7 year section 149 figure in this table is not this row's and there is no other to state.
If prescribed / medical: No entry for Memantine was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Memantine is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Memantine. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Memantine is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is a prescribed medicine in ordinary use, and the tier that governs dispensing and import for it was not opened by this reading.
Documentation: Carry the distinction this row rests on: the finding for Memantine is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Use the international non-proprietary name, because the sweep ran on it and no class heading was found that would reach this compound without it. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Memantine: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Memantine in Thailand, full detail →

Mephedrone (4-MMC)

Legal status: Mephedrone is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries mephedrone as an entry beneath it. This table's cathinone row is a closed list absence, so the parent name being unlisted does not soften the placement of mephedrone itself. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of Mephedrone triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. The cathinone row in this table is a closed list absence, so the parent name being unlisted does nothing to soften the section 145 exposure stated here for mephedrone itself.
If prescribed / medical: Mephedrone sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Mephedrone. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The route question does not arise, and the contrast with the unlisted parent is the point a reader is most likely to get backwards.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: Mephedrone was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check the individual compound name, because this table lists mephedrone, 3-MMC, methylone and MDPV and returns nothing for cathinone. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for Mephedrone is printed as mephedrone under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Mephedrone (4-MMC) in Thailand, full detail →

Mescaline

Legal status: Mescaline is a Category 1 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 1, psychotropic substances in category 1, and names mescaline beneath it. The mescaline entry is also what this table's peyote row runs through, since the cactus is not named. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for Mescaline that is the end of it: the maximum stated for a Category 1 psychotropic is 10 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. This same entry is what the peyote row runs through, since the cactus is not named, so the 10 year section 149 ceiling stated here reaches the plant through its constituent.
If prescribed / medical: Mescaline sits in psychotropic Category 1 under the B.E. 2565 naming notification, with a 10 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Mescaline. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The cactus has no line of its own in the notification, so a mescaline containing preparation is answered by this entry whatever it is called.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Mescaline is a Category 1 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check for mescaline content rather than for a plant name, because the notification names the molecule and not the cactus. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 10 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 1, where Mescaline is reached by the entry for mescaline · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Mescaline in Thailand, full detail →

Methadone

Legal status: Methadone is a Category II narcotic in Thailand. The Thai FDA table updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 2, narcotics subject to penalty of category 2, and names methadone beneath it. Methadone is named individually, and this table records no separate treatment programme exemption for it. Section 91 of the Narcotics Code B.E. 2564 is the Category II limb and section 146 carries its penalties, while the identity again comes from a Ministry of Public Health notification rather than from the Code. Category II is a different place in this scheme from Category I, and the difference is not cosmetic: it changes which penalty section applies and removes the limb that can reach life or death.
Consequences if caught: Capital exposure: none. Section 146 carries no death penalty and no life term at all, and that is the first thing to say about Methadone. The ceiling it states is up to 10 years, rising to 1 to 15 years where the Category II conduct is commerce or public dissemination. Section 145 paragraph 3, the only limb this dossier records as reaching life or death, governs Category I narcotics and does not follow a Category II substance. No quantity threshold is written into the section 146 penalty limb either, so weight is not what moves a case between those two bands. This table records no separate treatment programme exemption for methadone, so the section 146 exposure stated here is the general one and not a reduced one.
If prescribed / medical: Methadone sits in narcotics Category II under the 15 September 2025 table, and the placement is the classification rather than a statement about who may lawfully hold it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Methadone. A prescription does not move the entry out of Category II, and the route that a prescription or a foreign dispensing record would have to satisfy at the Thai border is precisely what was not read. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. A substitution programme route was not established in this reading, and buprenorphine, the other substitution medicine in this set, returned no entry in either instrument searched.
Documentation: Carry the prescription, the original dispensing packaging and a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and treat them as necessary rather than sufficient: this reading establishes only that Methadone is a Category II narcotic in the table updated 15 September 2025, and it does not establish what those papers achieve at a Thai port of entry. Check whether any programme documentation is recognised, because this table records no exemption for methadone and did not look for one. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 91 with the penalties at section 146 · Ministry of Public Health Category II naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where Methadone is reached by the entry printed as methadone under the category 2 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Methadone in Thailand, full detail →

Methamphetamine

Legal status: Methamphetamine is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries methamphetamine as an entry beneath it. The entry is the molecule, so a tablet presentation carries the same Category I placement as a crystalline one. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of Methamphetamine triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. The entry is the molecule, so a tablet presentation carries the same section 145 exposure as a crystalline one and the form makes no difference to the placement.
If prescribed / medical: Methamphetamine sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Methamphetamine. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. No medical route is answered here, and the form of the product is not a classification question in this scheme.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: Methamphetamine was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check the substance and not the presentation, because the table names the molecule and does not distinguish tablet from crystal. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for Methamphetamine is printed as methamphetamine under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Methamphetamine in Thailand, full detail →

Methaqualone (Quaaludes)

Legal status: Methaqualone is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries methaqualone as an entry beneath it. Methaqualone is a quinazolinone rather than a barbiturate, and this table's barbiturates row does not reach it. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of Methaqualone triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. Methaqualone is a quinazolinone and not a barbiturate, so the section 145 exposure stated here does not answer the barbiturates row in this table, which resolved nothing at all.
If prescribed / medical: Methaqualone sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Methaqualone. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is the nearest sedative hypnotic the table does answer, which is exactly why it should not be read as covering the barbiturate class.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: Methaqualone was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check that the compound is methaqualone itself, because the barbiturates row in this set was never resolved and this placement is not its answer. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for Methaqualone is printed as methaqualone under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Methaqualone (Quaaludes) in Thailand, full detail →

Methylone

Legal status: Methylone is a Category I narcotic in Thailand. The Thai FDA table of controlled narcotic drugs updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 1, narcotics subject to penalty of category 1, and carries methylone as an entry beneath it. Methylone is named individually, which is how this scheme reaches a cathinone derivative at all. The placement is not written into the Narcotics Code B.E. 2564 itself: section 90 leaves the names and the categories to Ministry of Public Health notification, and the FDA table is the consolidated republication of those notifications, read here through its last Category V entry. So the Code supplies the offence and the penalty while a notification supplies the identity, which is also why this status can move without the statute changing.
Consequences if caught: Capital exposure: only through section 145 paragraph 3, and only on that paragraph's own conditions. It is the narrow top of that section rather than the ordinary case: paragraph 3 permits 5 years to life plus a fine, or death, only where the actor leads or manages a criminal network or the conduct affects state security or public safety, so the death alternative is discretionary and circumstance based and no stated weight of Methylone triggers it. Ordinary conduct falls under section 145 paragraph 1, which allows up to 15 years. A traveller holding a personal quantity is in paragraph 1 territory and not in paragraph 3 territory. Paragraph 2 reaches 2 to 20 years for commerce, public dissemination and the listed aggravators. Nothing in that structure makes a quantity the switch between the limbs, which is the single point English summaries of Thai drug law most often get backwards. Methylone is named individually, which is how this scheme reaches a cathinone derivative at all, so section 145 follows the naming rather than the family.
If prescribed / medical: Methylone sits in narcotics Category I on the 15 September 2025 table, and that criminal classification is the whole of what this dossier settles about a person holding it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Methylone. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The individual naming is the whole mechanism here, and the unlisted parent cathinone shows what happens when it is missing.
Documentation: Carry the finding with its date attached rather than a document this row can vouch for: Methylone was read in Category I of the Thai FDA table of controlled narcotic drugs updated 15 September 2025, and no Thai permit, exemption or traveller allowance answering that placement was established here. Check the exact derivative named, because this table reaches methylone by listing it and reaches the parent cathinone not at all. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 90 with the penalties at section 145 · Ministry of Public Health Category I naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where the entry for Methylone is printed as methylone under the category 1 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026 through the table's last Category V entry. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Methylone in Thailand, full detail →

Methylphenidate

Legal status: Methylphenidate is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Both instruments read here are naming notifications made under the Narcotics Code, so the sweep could only return what those notifications name and the absence it returned is bounded by that. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Methylphenidate is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Methylphenidate is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Methylphenidate under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Methylphenidate is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Methylphenidate, if any, is not established here. Both instruments read here are naming notifications made under the Narcotics Code, so the sweep could only ever return what those notifications name, and the absence it returned is bounded by that and by nothing wider.
If prescribed / medical: No entry for Methylphenidate was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Methylphenidate is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Methylphenidate. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Methylphenidate is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is a prescribed medicine in ordinary use, and a traveller carrying it needs the medicines tier rather than the narcotics tier, which is the tier this reading did not open.
Documentation: Carry the distinction this row rests on: the finding for Methylphenidate is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Rely on the international non-proprietary name and the dispensing record, and treat the narcotics result as answering the narcotics question only. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Methylphenidate: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Methylphenidate in Thailand, full detail →

Mitragynine

Legal status: Neither mitragynine nor kratom is separately scheduled in Thailand: kratom was removed from Narcotics Category 5 by the Narcotics Act (No. 8) B.E. 2564 (2021), and mitragynine, the principal alkaloid of kratom, is a constituent of the now-legal plant, decriminalised together and regulated (not prohibited) under the Kratom Plant Act B.E. 2565 (2022), with sale to minors/pregnant women restricted. [Likely] That finding is carried forward from the entry published before this batch and was not re-derived from statute in this pass. Not confirmed for Mitragynine, and the reason is a reach question that did not settle rather than an absence that did. The search ran in Thai and in Latin script across the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices. The nearest entry it reached was kratom, and that was rejected because it is a different molecule and this scheme names molecules rather than families. The alkaloid and the leaf are different objects, and the near entry pulls in the opposite direction: this row rejected Kratom as an entry it reached, a rejected near entry is normally an entry that exists, and this table's kratom row nonetheless reports the leaf as a closed list absence, so the two rows contradict each other and that contradiction is unresolved here. A second check of the Narcotics Code's salts, derivatives and preparations language and of the Minister's notification power did not establish that Mitragynine is automatically caught, so the exact criminal classification remains open. This is not a finding that Mitragynine is uncontrolled in Thailand, and it is not a finding that the near entry catches it either.
Consequences if caught: Capital exposure: not established. No capital and no life exposure can be stated for Mitragynine and neither can be ruled out, because no category was proved and in this scheme the ceiling follows the placement: with the placement open there is no section 145, 146 or 149 figure to attach. The rejected near entry carries its own exposure and it is not this substance's, since kratom is recorded in this table as a closed list absence, which makes the near entry a weak anchor. If a later notification placed Mitragynine in Category I, the section 145 paragraph 3 death alternative would still be discretionary and circumstance based, reserved for an organised network leader or a state or public security impact, and never triggered by a stated quantity. Treat the risk as unquantified rather than as low.
If prescribed / medical: No proved schedule placement exists for Mitragynine in this reading, so there is no category to attach a medical or traveller route to. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Mitragynine. Two things are open at once here, the classification and the permission, and the second cannot be answered before the first. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. A kratom product is answered by the leaf row and by this alkaloid row differently, and by the 7-hydroxymitragynine row differently again.
Documentation: Carry the search record rather than a conclusion: for Mitragynine the sweep covered the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic notices, reached kratom as the nearest entry, rejected it as a different molecule, and stopped there. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, unresolved reach question for Mitragynine: searched in Thai and Latin script against the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the B.E. 2565 psychotropic naming notices, with kratom recorded as the rejected near entry and the Narcotics Code B.E. 2564 salts, derivatives and preparations language checked without result · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The finding in this cell is carried forward from the entry published before this batch and was not re-derived from statute in this pass · it is tagged [Likely] where it appears. · Updated September 21, 2026

Mitragynine in Thailand, full detail →

Modafinil

Legal status: Modafinil is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Modafinil returned no entry, and no wakefulness promoting class heading was found that would reach it without naming it. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Modafinil is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Modafinil is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Modafinil under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Modafinil is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Modafinil, if any, is not established here. No wakefulness promoting class heading was found that would reach modafinil without naming it, so there is no class route to a section figure and no named route either.
If prescribed / medical: No entry for Modafinil was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Modafinil is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Modafinil. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Modafinil is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is a prescribed medicine in ordinary use, and the tier that governs its supply and its import was not opened by this reading.
Documentation: Carry the distinction this row rests on: the finding for Modafinil is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Use the international non-proprietary name, because the sweep found neither that name nor any class heading that would cover it. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Modafinil: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Modafinil in Thailand, full detail →

Morphine

Legal status: Morphine is a Category II narcotic in Thailand. The Thai FDA table updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 2, narcotics subject to penalty of category 2, and names morphine beneath it. Morphine sits in Category II while heroin, which is derived from it, sits in Category I under a different penalty section. Section 91 of the Narcotics Code B.E. 2564 is the Category II limb and section 146 carries its penalties, while the identity again comes from a Ministry of Public Health notification rather than from the Code. Category II is a different place in this scheme from Category I, and the difference is not cosmetic: it changes which penalty section applies and removes the limb that can reach life or death.
Consequences if caught: Capital exposure: none. Section 146 carries no death penalty and no life term at all, and that is the first thing to say about Morphine. The ceiling it states is up to 10 years, rising to 1 to 15 years where the Category II conduct is commerce or public dissemination. Section 145 paragraph 3, the only limb this dossier records as reaching life or death, governs Category I narcotics and does not follow a Category II substance. No quantity threshold is written into the section 146 penalty limb either, so weight is not what moves a case between those two bands. Morphine sits in Category II under section 146 while heroin, which is derived from it, sits in Category I under section 145, so derivation runs the opposite way from the exposure.
If prescribed / medical: Morphine sits in narcotics Category II under the 15 September 2025 table, and the placement is the classification rather than a statement about who may lawfully hold it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Morphine. A prescription does not move the entry out of Category II, and the route that a prescription or a foreign dispensing record would have to satisfy at the Thai border is precisely what was not read. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is the opiate the table treats as medical, while the compound derived from it carries the heavier section.
Documentation: Carry the prescription, the original dispensing packaging and a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and treat them as necessary rather than sufficient: this reading establishes only that Morphine is a Category II narcotic in the table updated 15 September 2025, and it does not establish what those papers achieve at a Thai port of entry. Check which of the two is named, because the derived compound and the parent sit in different categories in this table. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 91 with the penalties at section 146 · Ministry of Public Health Category II naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where Morphine is reached by the entry printed as morphine under the category 2 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Morphine in Thailand, full detail →

Nicotine

Legal status: Nicotine is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Nicotine is regulated through tobacco control rather than through the Narcotics Code, and this row establishes only the second half of that. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Nicotine is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Nicotine is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Nicotine under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Nicotine is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Nicotine, if any, is not established here. Nicotine is regulated through tobacco control rather than through the Narcotics Code, and this row establishes only the second half of that, so the missing Code figure is not the useful fact here.
If prescribed / medical: No entry for Nicotine was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Nicotine is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Nicotine. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Nicotine is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Replacement therapy and vaping products are governed by instruments this reading did not open, and Thailand's rules on the latter are not established here.
Documentation: Carry the distinction this row rests on: the finding for Nicotine is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Draw no inference to vaping or e-liquid products, because those run on tobacco and product instruments that were never read. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Nicotine: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Nicotine in Thailand, full detail →

Nimetazepam

Legal status: Nimetazepam is a Category 2 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 2, psychotropic substances in category 2, and names nimetazepam beneath it. Nimetazepam sits in Category 2 with alprazolam rather than in Category 4 with the other benzodiazepines this table answers. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for Nimetazepam that is the end of it: the maximum stated for a Category 2 psychotropic is 7 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. Nimetazepam sits in Category 2 with alprazolam rather than in Category 4 with the other benzodiazepines this table answers, so its 7 year ceiling is the higher of the two this notification gives them.
If prescribed / medical: Nimetazepam sits in psychotropic Category 2 under the B.E. 2565 naming notification, with a 7 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Nimetazepam. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The class label does not predict the category here, which is the single reason the benzodiazepines row in this table can state no status at all.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Nimetazepam is a Category 2 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check the individual name against the notification, because two of the benzodiazepines in this set are Category 2 and three are Category 4. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 7 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 2, where Nimetazepam is reached by the entry for nimetazepam · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Nimetazepam in Thailand, full detail →

Nitrous Oxide

Legal status: Nitrous oxide is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Nitrous oxide returned no entry, and the gas is reached, if at all, by instruments that were not opened here. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Nitrous oxide is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Nitrous oxide is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Nitrous oxide under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Nitrous oxide is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Nitrous oxide, if any, is not established here. The gas is reached, if at all, by instruments that were not opened here, so the missing section 145, 146, 148 or 149 figure is a gap in what was read and not a ceiling of zero.
If prescribed / medical: No entry for Nitrous oxide was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Nitrous oxide is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Nitrous oxide. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Nitrous oxide is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Nitrous oxide is a medical gas as well as a recreational one, and neither the medical supply route nor the food grade route was read.
Documentation: Carry the distinction this row rests on: the finding for Nitrous oxide is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Keep the medical, food grade and recreational supply questions apart, because none of the three was answered by the instruments read here. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Nitrous oxide: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Nitrous Oxide in Thailand, full detail →

Opium

Legal status: Opium is a Category II narcotic in Thailand. The Thai FDA table updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 2, narcotics subject to penalty of category 2, and names opium beneath it. Opium is named as the raw material, and the table places it with the medical opiates rather than with heroin. Section 91 of the Narcotics Code B.E. 2564 is the Category II limb and section 146 carries its penalties, while the identity again comes from a Ministry of Public Health notification rather than from the Code. Category II is a different place in this scheme from Category I, and the difference is not cosmetic: it changes which penalty section applies and removes the limb that can reach life or death.
Consequences if caught: Capital exposure: none. Section 146 carries no death penalty and no life term at all, and that is the first thing to say about Opium. The ceiling it states is up to 10 years, rising to 1 to 15 years where the Category II conduct is commerce or public dissemination. Section 145 paragraph 3, the only limb this dossier records as reaching life or death, governs Category I narcotics and does not follow a Category II substance. No quantity threshold is written into the section 146 penalty limb either, so weight is not what moves a case between those two bands. Opium is named as the raw material and the table places it with the medical opiates rather than with heroin, so section 146 and not section 145 states the ceiling.
If prescribed / medical: Opium sits in narcotics Category II under the 15 September 2025 table, and the placement is the classification rather than a statement about who may lawfully hold it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Opium. A prescription does not move the entry out of Category II, and the route that a prescription or a foreign dispensing record would have to satisfy at the Thai border is precisely what was not read. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The raw material and the compound derived from it part company in this table, and the raw material is on the lighter section.
Documentation: Carry no expectation that paperwork answers this row, because Opium is not something a traveller is dispensed: what was established is a Category II placement in the Thai FDA table updated 15 September 2025, which is a criminal classification and not a permit question, and no Thai exemption or allowance for it was established here. Check whether the finding relied on is the raw material line or a derived compound, because this table separates them. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 91 with the penalties at section 146 · Ministry of Public Health Category II naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where Opium is reached by the entry printed as opium under the category 2 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Opium in Thailand, full detail →

Oxycodone

Legal status: Oxycodone is a Category II narcotic in Thailand. The Thai FDA table updated 15 September 2025 prints the heading ยาเสพติดให้โทษประเภท 2, narcotics subject to penalty of category 2, and names oxycodone beneath it. Oxycodone is named individually, so its placement does not depend on being read as a morphine derivative. Section 91 of the Narcotics Code B.E. 2564 is the Category II limb and section 146 carries its penalties, while the identity again comes from a Ministry of Public Health notification rather than from the Code. Category II is a different place in this scheme from Category I, and the difference is not cosmetic: it changes which penalty section applies and removes the limb that can reach life or death.
Consequences if caught: Capital exposure: none. Section 146 carries no death penalty and no life term at all, and that is the first thing to say about Oxycodone. The ceiling it states is up to 10 years, rising to 1 to 15 years where the Category II conduct is commerce or public dissemination. Section 145 paragraph 3, the only limb this dossier records as reaching life or death, governs Category I narcotics and does not follow a Category II substance. No quantity threshold is written into the section 146 penalty limb either, so weight is not what moves a case between those two bands. Oxycodone is named individually, so its section 146 exposure does not depend on being read as a morphine derivative.
If prescribed / medical: Oxycodone sits in narcotics Category II under the 15 September 2025 table, and the placement is the classification rather than a statement about who may lawfully hold it. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Oxycodone. A prescription does not move the entry out of Category II, and the route that a prescription or a foreign dispensing record would have to satisfy at the Thai border is precisely what was not read. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The individual naming is what settles this row, and a derivative argument would not have reached it.
Documentation: Carry the prescription, the original dispensing packaging and a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and treat them as necessary rather than sufficient: this reading establishes only that Oxycodone is a Category II narcotic in the table updated 15 September 2025, and it does not establish what those papers achieve at a Thai port of entry. Check for the individual name, because this table does not reach oxycodone through the morphine entry. The reading was taken on 20 September 2026 from the consolidated narcotics table, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 91 with the penalties at section 146 · Ministry of Public Health Category II naming notification as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, where Oxycodone is reached by the entry printed as oxycodone under the category 2 heading · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Oxycodone in Thailand, full detail →

PCP

Legal status: PCP is a Category 1 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 1, psychotropic substances in category 1, and names PCP beneath it. PCP is named in the notification in its own right rather than being read out of the ketamine entry, which sits in a different psychotropic category. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for PCP that is the end of it: the maximum stated for a Category 1 psychotropic is 10 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. PCP is named in the notification in its own right rather than read out of the ketamine entry, which sits a category lower at a 7 year section 149 maximum, so the two dissociatives this table places do not share a ceiling.
If prescribed / medical: PCP sits in psychotropic Category 1 under the B.E. 2565 naming notification, with a 10 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for PCP. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The separate naming puts this compound above ketamine in the same notification, which is the comparison most likely to be assumed the other way round.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for PCP is a Category 1 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check which dissociative is named, because this notification puts PCP in Category 1 and ketamine in Category 2. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 10 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 1, where PCP is reached by the entry for PCP · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

PCP in Thailand, full detail →

Peyote

Legal status: Peyote is reached through the mescaline entry in Thailand's psychotropic Category 1. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 1, psychotropic substances in category 1, and names mescaline beneath it. Peyote is not named as a cactus. A mescaline preparation is caught by the Category 1 psychotropic entry, so the plant is reached through what it contains. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149(1) provides neither a death penalty nor life imprisonment, and for Peyote that is the end of it: the maximum stated for a Category 1 psychotropic is 10 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. Peyote is not named as a cactus, so the 10 year ceiling stated here is the mescaline entry's, reached through what the plant contains.
If prescribed / medical: Peyote sits in psychotropic Category 1 under the B.E. 2565 naming notification, with a 10 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Peyote. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The plant has no entry of its own, so a preparation is answered by whether mescaline is in it and not by botanical identity.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Peyote is a Category 1 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check for mescaline content, because the notification names the molecule and not the cactus that carries it. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 10 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 1, where Peyote is reached by the entry for mescaline · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Peyote in Thailand, full detail →

Phenibut

Legal status: Phenibut is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Phenibut returned no entry, and no analogue clause was found that would reach it through any listed compound. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Phenibut is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Phenibut is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Phenibut under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Phenibut is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Phenibut, if any, is not established here. No analogue clause was found that would reach phenibut through any listed compound, so neither a named route nor a class route to a section figure exists in what was read.
If prescribed / medical: No entry for Phenibut was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Phenibut is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Phenibut. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Phenibut is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is sold as a supplement in some countries and as a medicine in others, and which of those Thailand treats it as was not established here.
Documentation: Carry the distinction this row rests on: the finding for Phenibut is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Keep the supplement question and the medicine question apart, because the instruments read here answer neither of them. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Phenibut: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Phenibut in Thailand, full detail →

Pink Cocaine / Tusi

Legal status: Not applicable as a single status, and not because the notifications are silent. Pink cocaine is a street label rather than a substance: the dossier records it as a family or street-market label and not one fixed chemical entry, with every constituent to be checked against the Thai notifications separately. Thai control is closed and delegated, working entry by entry through Ministry of Public Health notifications, so a powder sold under this name is whatever it analyses as, and the same name can produce different results from one sample to the next. The constituents commonly reported under it are answered separately in this table and they do not agree: ketamine is a psychotropic Category 2 substance, MDMA, methamphetamine and 2C-B are each Category I narcotics, and caffeine is a closed list absence. Those rows, not this one, carry the schedule placements, and no single terminal status can honestly be stated for the label itself.
Consequences if caught: Capital exposure: reachable through three of the constituents this label covers and not through the other two. Whether it is present depends entirely on what the powder is, which is the whole problem with this label: a 2C-B, MDMA or methamphetamine result puts a person under section 145, whose paragraph 3 reaches 5 years to life plus a fine, or death, though only for an organised network leader or a state or public security impact and never by quantity, while a ketamine result caps at the 7 year section 149 maximum for a Category 2 psychotropic and carries no capital or life limb at all. The same name therefore spans the widest penalty gap in this table. No single ceiling attaches to the label, and a buyer cannot know which one applies without an analysis.
If prescribed / medical: There is no prescription route to state, because there is no single substance to attach one to and none of the constituents is dispensed under this name. The medical questions belong to the constituent rows, where ketamine's Category 2 psychotropic placement and the Category I placements of MDMA, methamphetamine and 2C-B each answer a different question. Thailand's country level traveller rule for personal medication was not established by this reading in any event, so even a constituent row could not supply a permit route, a quantity ceiling or a certificate requirement.
Documentation: Carry no assumption from the name, because it does not identify a substance: what is held is whatever the powder analyses as, and this table answers the reported constituents individually under ketamine, MDMA, methamphetamine, 2C-B and caffeine. Read those rows rather than this one for any placement or ceiling. The label finding was taken on 20 September 2026 against the Narcotics Code B.E. 2564 as promulgated in the Royal Gazette, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2564/A/073/T_0001.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link.

Thailand, street label with no single placement: the Narcotics Code B.E. 2564 delegates the naming of ยาเสพติดให้โทษ, narcotics subject to penalty, to ministerial notification entry by entry, so the label is resolved through its constituents' own rows, which run from a Category I narcotic placement under section 145 to a Category 2 psychotropic placement under section 149 and a closed list absence · read at https://www.ratchakitcha.soc.go.th/DATA/PDF/2564/A/073/T_0001.PDF on 20 September 2026, with the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf carrying the constituent entries. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Pink Cocaine / Tusi in Thailand, full detail →

Poppers

Legal status: Not applicable as a single status, and not because the notifications are silent. Poppers is a market label for a group of alkyl nitrite preparations rather than one chemical entry: the dossier records it as a family or street-market label with every constituent to be checked against the Thai notifications separately. Thai control is closed and delegated, so what is in the bottle decides the outcome and the brand name on it decides nothing. The constituent this table does answer is amyl nitrite, and that row is a closed list absence, meaning no narcotic or psychotropic entry was found for it; other alkyl nitrites sold under the same label were not swept individually here. That row and any future constituent row, not this one, carry the placements, so no single terminal status can honestly be stated for the label.
Consequences if caught: Capital exposure: not established for this label, because its constituents were not all swept. Neither a death penalty nor a life term attaches to this label through the Narcotics Code, because the label has no category and the one constituent this table answers has none either: with no Category I, II, IV, V or psychotropic entry for amyl nitrite there is no section 145, 146, 148 or 149 ceiling to state. That is a closed list negative finding about the drug schedules and not a clearance, since the poisons, medicines and product laws carry their own penalties and were outside this reading. A different nitrite in the bottle is a different question again, and it was not swept.
If prescribed / medical: No prescription route arises, because no constituent answered here has a schedule placement to be prescribed out of, and poppers are not dispensed as a medicine under this name. Amyl nitrite has genuine medical uses, and whether Thailand treats it as a prescription only medicine or a controlled import sits in the medicines and poisons laws rather than in the narcotics notifications that were read. Thailand's country level traveller rule was not established by this reading either, so nothing here states what a traveller may carry or under what paperwork.
Documentation: Carry the actual chemical name from the bottle rather than the market label, because the two are not the same object and only the first can be searched against a Thai notification. This table's amyl nitrite row is the only constituent answered, and it records an absence from the criminal schedules rather than a clearance under the medicines, poisons or product laws. The label finding was taken on 20 September 2026 against the Narcotics Code B.E. 2564 in the Royal Gazette, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2564/A/073/T_0001.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link.

Thailand, market label with no single placement: the Narcotics Code B.E. 2564 delegates naming to ministerial notification entry by entry, and the constituent answered in this set, amyl nitrite, returned a closed list absence against the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the B.E. 2565 psychotropic naming notifications, so no ceiling attaches to the label · the Code was read at https://www.ratchakitcha.soc.go.th/DATA/PDF/2564/A/073/T_0001.PDF on 20 September 2026 and the table at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Poppers in Thailand, full detail →

Pregabalin

Legal status: Pregabalin is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Pregabalin returned no entry, matching the gabapentin result in this same table. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Pregabalin is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Pregabalin is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Pregabalin under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Pregabalin is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Pregabalin, if any, is not established here. The gabapentin result in this same table matches, so two gabapentinoids were swept and both returned nothing, and a matching absence in two rows is still an absence from two documents.
If prescribed / medical: No entry for Pregabalin was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Pregabalin is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Pregabalin. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Pregabalin is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is a prescribed medicine in ordinary use, and the phenibut row in this set is a third related absence, so three neighbouring compounds here are all unanswered on the medicines side.
Documentation: Carry the distinction this row rests on: the finding for Pregabalin is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Read the gabapentin result alongside this one, because the two rows were swept the same way and returned the same thing. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Pregabalin: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Pregabalin in Thailand, full detail →

Psilocybin

Legal status: Psilocybin is a Category 1 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 1, psychotropic substances in category 1, and names psilocybin beneath it. The notification names the molecule; the mushroom that carries it is not a separate entry in what was read. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for Psilocybin that is the end of it: the maximum stated for a Category 1 psychotropic is 10 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. The notification names the molecule and the mushroom that carries it is not a separate entry in what was read, so the 10 year ceiling attaches through content rather than through the fruiting body.
If prescribed / medical: Psilocybin sits in psychotropic Category 1 under the B.E. 2565 naming notification, with a 10 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Psilocybin. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. Amanita muscaria, the other mushroom this table answers, returned no entry in either instrument searched, so the two mushrooms in this set are not answered by the same finding.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Psilocybin is a Category 1 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check what a preparation contains, because the notification names psilocybin and no mushroom was found as an entry of its own. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 10 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 1, where Psilocybin is reached by the entry for psilocybin · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Psilocybin in Thailand, full detail →

Quetiapine

Legal status: Quetiapine is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Quetiapine returned no entry, which is what a prescription antipsychotic outside the psychotropic notifications looks like on this list. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Quetiapine is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Quetiapine is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Quetiapine under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Quetiapine is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Quetiapine, if any, is not established here. Quetiapine returned no entry, which is what a prescription medicine outside the psychotropic notifications looks like on this list, and what it looks like is not what it proves.
If prescribed / medical: No entry for Quetiapine was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Quetiapine is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Quetiapine. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Quetiapine is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is a prescribed medicine in ordinary use, and a medicine of this kind is exactly what a medicines statute rather than a narcotics notification would govern.
Documentation: Carry the distinction this row rests on: the finding for Quetiapine is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Rely on the dispensing record and on the international non-proprietary name, and note that no psychotropic category was found attaching to this medicine at all. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Quetiapine: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Quetiapine in Thailand, full detail →

Salvia divinorum

Legal status: Salvia divinorum is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Neither the plant nor salvinorin A was found as an entry in what was read. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Salvia divinorum is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Salvia divinorum is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Salvia divinorum under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Salvia divinorum is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Salvia divinorum, if any, is not established here. Neither the plant nor salvinorin A was found as an entry in what was read, so there is no constituent line in those two instruments carrying an exposure the plant does not.
If prescribed / medical: No entry for Salvia divinorum was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Salvia divinorum is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Salvia divinorum. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Salvia divinorum is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. No medical route is in question, and what this row leaves unanswered is the herbal product and plant import side.
Documentation: Carry the distinction this row rests on: the finding for Salvia divinorum is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Search both names, the plant and salvinorin A, because the sweep looked for each of them and returned nothing for either. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Salvia divinorum: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Salvia divinorum in Thailand, full detail →

Scopolamine (Devil's Breath)

Legal status: Scopolamine is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Scopolamine returned no entry, so its Thai handling runs through instruments this reading did not open. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Scopolamine is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Scopolamine is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Scopolamine under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Scopolamine is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Scopolamine, if any, is not established here. Scopolamine's Thai handling runs through instruments this reading did not open, so the missing Code section marks where the reading stopped and not where the control stops.
If prescribed / medical: No entry for Scopolamine was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Scopolamine is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Scopolamine. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Scopolamine is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is a medicine in ordinary use, dispensed as patches and as tablets, and the tier that governs that in Thailand was not read.
Documentation: Carry the distinction this row rests on: the finding for Scopolamine is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Rely on the dispensing record and the international non-proprietary name, because what was established here is a narcotics and psychotropic result only. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Scopolamine: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Scopolamine (Devil's Breath) in Thailand, full detail →

Synthetic Cannabinoids (K2 / Spice)

Legal status: Not applicable as a class status, and not because the notifications are silent. Synthetic cannabinoids is a class label covering many unrelated molecules rather than one entry: the dossier records it as a family or street-market label with every constituent to be checked against the Thai notifications separately. Thailand's model makes this decisive, because control is delegated to notifications that name substances individually and no generic analogue clause was identified in that model, so a synthetic cannabinoid is reached only if a notification names it. The cannabinoid molecules this table does answer are HHC, THC-P, delta-8-THC and cannabinol, and every one of them is an unresolved reach question that rejected the tetrahydrocannabinol entry as a different molecule. Those rows, not this one, carry what was and was not established, and no single terminal status can honestly be stated for the class.
Consequences if caught: Capital exposure: not established. No capital and no life exposure can be stated for the class and neither can be ruled out, because the class has no placement and the four cannabinoid rows this table answers are each open: the ceiling follows the placement, and with no proved category there is no section 145, 146, 148 or 149 figure to attach. A named entry in Category I would bring section 145 paragraph 3 into reach, where 5 years to life plus a fine, or death, is available only for an organised network leader or a state or public security impact, discretionary and never quantity triggered. A cannabis extract question runs instead to Category V and section 148, up to 5 years or 1 to 15 years aggravated, with no capital limb. Which of those a given product falls into is unresolved, so treat the exposure as unquantified.
If prescribed / medical: No prescription route exists for the class, and none of the molecules this table answers under it has a proved placement to attach one to. The cannabis prescription position is a different matter entirely, running through the licensed medical channel of the B.E. 2568 controlled herb notification, and it does not extend to a synthetic cannabinoid sold as a product. Thailand's country level traveller rule for personal medication was not established by this reading, so no permit route, quantity ceiling or certificate requirement can be stated for anything in this class.
Documentation: Carry the specific molecule name, because the class label cannot be searched against a Thai notification and the molecule can: this table answers HHC, THC-P, delta-8-THC and cannabinol individually, each as an unsettled reach question rather than a finding either way, and a JWH, AM or MDMB series compound was not swept here at all. Treat a herbal product sold as a cannabinoid blend as unidentified until analysed. The label finding was taken on 20 September 2026 against the Narcotics Code B.E. 2564 in the Royal Gazette, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2564/A/073/T_0001.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link.

Thailand, class label with no single placement: the Narcotics Code B.E. 2564 delegates naming to ministerial notification and no generic analogue clause was identified, so control requires a named entry · the cannabinoid molecules answered in this set, HHC, THC-P, delta-8-THC and cannabinol, are each recorded as unresolved against the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the B.E. 2565 psychotropic naming notices, having rejected the tetrahydrocannabinol entry · the Code was read at https://www.ratchakitcha.soc.go.th/DATA/PDF/2564/A/073/T_0001.PDF on 20 September 2026 and the table at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Synthetic Cannabinoids (K2 / Spice) in Thailand, full detail →

Tobacco

Legal status: Tobacco is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Tobacco is regulated by its own control law and not by the narcotics notifications, and only the second half of that is established here. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Tobacco is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Tobacco is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Tobacco under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Tobacco is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Tobacco, if any, is not established here. Tobacco is regulated by its own control law and not by the narcotics notifications, and only the second half of that is established here, so the missing Code figure says very little.
If prescribed / medical: No entry for Tobacco was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Tobacco is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Tobacco. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Tobacco is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. No prescription route is in question, and what this row leaves unanswered is the tobacco control, excise and import side.
Documentation: Carry the distinction this row rests on: the finding for Tobacco is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Treat the import allowance question separately, because tobacco allowances run on customs and tobacco control instruments that were not read. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Tobacco: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Tobacco in Thailand, full detail →

Tramadol

Legal status: Tramadol is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Tramadol returned no entry while codeine, morphine and oxycodone are each named in Category II, so it is not in the same position as the other opioids this table answers. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Tramadol is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Tramadol is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Tramadol under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Tramadol is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Tramadol, if any, is not established here. Codeine, morphine and oxycodone are each named in Category II under section 146 while tramadol returned nothing, and a difference inside one table is not by itself a difference in Thai law.
If prescribed / medical: No entry for Tramadol was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Tramadol is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Tramadol. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Tramadol is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is a prescribed analgesic in ordinary use, and the medicines tier that would govern carrying it is the tier this reading did not open.
Documentation: Carry the distinction this row rests on: the finding for Tramadol is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Rely on the dispensing record and on the international non-proprietary name, and do not read this table's Category II opioid entries as covering it. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Tramadol: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Tramadol in Thailand, full detail →

Xanax (Alprazolam)

Legal status: Alprazolam is a Category 2 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 2, psychotropic substances in category 2, and names alprazolam beneath it. Alprazolam sits a category above diazepam, clonazepam and lorazepam in the same notification, and this table's etizolam row records alprazolam as the near entry it rejected. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for Alprazolam that is the end of it: the maximum stated for a Category 2 psychotropic is 7 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. Alprazolam sits a category above diazepam, clonazepam and lorazepam in the same notification, so the 7 year figure stated here is two years above the ceiling those three carry.
If prescribed / medical: Alprazolam sits in psychotropic Category 2 under the B.E. 2565 naming notification, with a 7 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Alprazolam. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The etizolam row in this table rejected alprazolam as a near entry, so a thienotriazolodiazepine is not answered by this placement.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Alprazolam is a Category 2 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check which benzodiazepine is named, because this notification splits the ones in this set between Category 2 and Category 4. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 7 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 2, where Alprazolam is reached by the entry for alprazolam · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Xanax (Alprazolam) in Thailand, full detail →

Xylazine

Legal status: Xylazine is not named in Thailand's criminal drug schedules. A substance specific sweep, run in Thai and by chemical name, found no entry for it in the Thai FDA table of controlled narcotic drugs updated 15 September 2025 and none in the B.E. 2565 psychotropic naming notifications, and no generic analogue clause was identified in the naming model that would reach it without naming it. Xylazine returned no entry, and it is a veterinary sedative rather than a scheduled narcotic under what was read. That is a positive finding on a closed list rather than an unresolved search: Thai control is delegated to notifications that name substances one by one, so what the notifications do not name sits outside the Narcotics Code's categories until one names it. It is not a finding that Xylazine is uncontrolled in Thailand. Two instruments were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, and Thailand also controls medicines through the Drug Act B.E. 2510, which this reading did not open. Which tier of that Act, if any, reaches Xylazine is not established here.
Consequences if caught: Capital exposure: none. No death penalty and no life term arises for Xylazine under the Narcotics Code, and the reason is structural rather than lenient: the Narcotics Code's penalties attach to a scheduled category, the sweep placed this substance in none of them, and with no Category I, II, IV, V or psychotropic entry there is no section 145, 146, 148 or 149 ceiling to state at all. No capital or life exposure under that Code attaches to a closed list negative finding. The sweep that produced this ran across two instruments and no others, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so it is an absence from those two and not a finding that Xylazine is uncontrolled in Thailand. What it does not cover is the Drug Act B.E. 2510, the separate medicines statute with its own tiers and its own penalties, which this reading did not open, so which tier of that Act reaches Xylazine, if any, is not established here. Xylazine is a veterinary sedative rather than a scheduled narcotic under what was read, so a veterinary medicines route is where a figure would come from and that route was not opened.
If prescribed / medical: No entry for Xylazine was found in either of the two instruments that were searched, the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and the Ministry of Public Health psychotropic naming notifications of B.E. 2565, so no narcotic or psychotropic schedule places it and none can carry a prescription route. That is an absence from those two instruments and it is not a finding that Xylazine is uncontrolled in Thailand. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Xylazine. Thailand controls medicines separately under the Drug Act B.E. 2510, and that Act and its tiers were not opened by this reading, so whether Xylazine is a prescription only medicine, a restricted import or freely carried under it is not established here. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. This is not dispensed to people at all, so what this row leaves unanswered is a veterinary supply question rather than a traveller prescription one.
Documentation: Carry the distinction this row rests on: the finding for Xylazine is an absence from the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025 and from the Ministry of Public Health psychotropic naming notifications of B.E. 2565, which is not a clearance under Thai law generally, so any paperwork it needs would come from the Drug Act B.E. 2510 rather than from the Narcotics Code, and this reading did not open that Act to say which of its tiers, if any, applies. Keep the veterinary framing, because a human medicines check would not find this compound and the instruments read here did not find it either. The reading was taken on 20 September 2026 from the consolidated narcotics table, read alongside the psychotropic naming notices, at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, closed list negative finding for Xylazine: no entry in the Ministry of Public Health narcotic naming notifications as consolidated in the Thai FDA Table of Controlled Narcotic Drugs updated 15 September 2025, and none in the B.E. 2565 psychotropic naming notifications · the naming power is delegated by the Narcotics Code B.E. 2564 and no generic analogue clause was identified · read at https://narcotic.fda.moph.go.th/media.php?id=808160206197497856&name=NARCO+list+(update+15.09.2025)+NEW.pdf on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Xylazine in Thailand, full detail →

Zolpidem

Legal status: Zolpidem is a Category 4 psychotropic substance in Thailand. The Ministry of Public Health naming notification published in the Royal Gazette in B.E. 2565 prints วัตถุออกฤทธิ์ในประเภท 4, psychotropic substances in category 4, and names zolpidem beneath it. Zolpidem is not a benzodiazepine, and it is placed in the same Category 4 as the three this table answers there. Section 94 of the Narcotics Code B.E. 2564 is the psychotropic limb and section 149 carries the penalties. This is the criminal classification taken from the naming notification and not from a traveller permit label, and the two are different documents answering different questions.
Consequences if caught: Capital exposure: none. Section 149 provides neither a death penalty nor life imprisonment, and for Zolpidem that is the end of it: the maximum stated for a Category 4 psychotropic is 5 years, with no death penalty, no life imprisonment and no quantity threshold as the trigger. The limb of this Code that can reach life or death is section 145 paragraph 3, it belongs to Category I narcotics, and a psychotropic placement does not carry a person into it. English accounts that merge the narcotic categories with the psychotropic categories produce exactly that error, and it is the reason this row states the ceiling before anything else. Zolpidem is not a benzodiazepine and is placed in the same Category 4 as the three this table answers there, so the 5 year ceiling is shared across a chemical boundary.
If prescribed / medical: Zolpidem sits in psychotropic Category 4 under the B.E. 2565 naming notification, with a 5 year section 149 maximum, and that placement is a classification rather than a permission. Thailand's country level traveller rule for personal medication was not established by this reading. The sources opened were the Narcotics Code B.E. 2564, the Thai FDA narcotics table updated 15 September 2025 and the B.E. 2565 psychotropic naming notices in the Royal Gazette, and the dossier is explicit that its findings come from those naming instruments and not from a traveller permit label, so no import permit route, no personal supply quantity ceiling and no certificate requirement can be stated here for Zolpidem. The notification read here is the criminal naming instrument and not the permit schedule, so it cannot say whether a foreign prescription, a quantity limit or an advance certificate would make a lawful entry. What is missing from this row is the permission, not the classification, and the gap is in what was read rather than a finding that no lawful route exists. The category here does not track the chemistry, which is why a class based expectation about this medicine would be wrong in both directions.
Documentation: Carry the prescription and the original dispensing packaging with a doctor's letter naming the patient, the active ingredient, the dose and the treatment period, and do not assume they settle the question: what was established for Zolpidem is a Category 4 psychotropic placement in the B.E. 2565 naming notification, not a traveller route. Check the category rather than the drug class, because this notification puts a non benzodiazepine in with the benzodiazepines. The reading was taken on 20 September 2026 from the Royal Gazette psychotropic naming notification, at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. The names and categories are set by ministerial notification, and the publications do not certify that no later notification exists, so re-read before relying on this.

Thailand, Narcotics Code B.E. 2564 section 94 with the penalties at section 149 and a stated maximum of 5 years · Ministry of Public Health psychotropic naming notification B.E. 2565, category 4, where Zolpidem is reached by the entry for zolpidem · read in the Royal Gazette at https://www.ratchakitcha.soc.go.th/DATA/PDF/2565/E/182/T_0008.PDF on 20 September 2026. No express open reuse licence was located on the cited page, so only the wording needed for verification is reproduced, with attribution and a direct link. · Updated September 21, 2026

Zolpidem in Thailand, full detail →

Not individually verified

14 substances are not individually verified for Thailand

For these the governing national drug law is cited, but we have not verified that the substance specifically is scheduled under it. Treat them as unanswered, not as legal. Confirm with Thailand’s drug authority or your embassy.

Substance	What we found
1P-LSD	Not confirmed for 1P-LSD, and the reason is a reach question that did not settle rather than an absence that did....
2-FDCK	Not confirmed for 2-FDCK, and the reason is a reach question that did not settle rather than an absence that did....
2C-E	Not confirmed for 2C-E, and the reason is a reach question that did not settle rather than an absence that did. The...
2C-I	Not confirmed for 2C-I, and the reason is a reach question that did not settle rather than an absence that did. The...
2C-T-7	Not confirmed for 2C-T-7, and the reason is a reach question that did not settle rather than an absence that did....
4-AcO-DMT	Not confirmed for 4-AcO-DMT, and the reason is a reach question that did not settle rather than an absence that did....
4-HO-MET	Not confirmed for 4-HO-MET, and the reason is a reach question that did not settle rather than an absence that did....
5-MeO-DMT (Bufo / Toad)	Not confirmed for 5-MeO-DMT, and the reason is a reach question that did not settle rather than an absence that did....
6-APB	Not confirmed for 6-APB, and the reason is a reach question that did not settle rather than an absence that did. The...
Barbiturates	Not confirmed, and the honest reason is that this table carries no barbiturate to resolve the class from....
HHC	Not confirmed for HHC, and the reason is a reach question that did not settle rather than an absence that did. The...
LSA (Morning Glory)	Not confirmed for LSA, and the reason is a reach question that did not settle rather than an absence that did. The...
MXE	Not confirmed for MXE, and the reason is a reach question that did not settle rather than an absence that did. The...
THC-P	Not confirmed for THC-P, and the reason is a reach question that did not settle rather than an absence that did. The...

Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.

Before you travel

Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.

If you’re detained or arrested abroad

Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →

← All countries Drug index